most common localization of CMV disease is retinitis, but colitis, pneumonitis, esophagitis, and neurological disease are other possible manifestations [1, 2] . CMV retinitis causes loss of vision and blindness but has also been shown to be associated with increased mortality [4] . As a manifestation of systemic disease, CMV retinitis requires systemic anti-CMV therapy [2, 5] . Therapy reverses or stabilizes ocular lesions and also reduces or delays mortality [6] . Although ART has led to a marked reduction of its incidence [7, 8] , CMV disease remains a threat for patients with advanced immunosuppression [3] . Even in the ART era, it has been shown that CMV retinitis remains associated with increased mortality [9] and that systemic therapy reduces this risk [10] . Finally, evidence shows that CMV viremia is common in patients with advanced human immunodeficiency virus (HIV) disease and that it is associated with both occurrence of CMV disease [11] [12] [13] [14] and increased mortality, even in patients on ART [9, [13] [14] [15] .
Despite this compelling evidence, CMV disease in AIDS patients in resource-limited settings (RLS) has largely been ignored. This has stemmed in particular from the prohibitive cost and inaccessibility of CMV medicines, notably oral valganciclovir, lack of awareness, and systematic screening of retinitis in patients with profound immunosuppression, and lack of research and funding support [16] . Yet some studies do show that CMV retinitis is frequent in AIDS patients in developing countries, notably in Asia [16] [17] [18] . When CMV retinitis is diagnosed, patients are often left untreated. To circumvent lack of access to systemic therapy and intraocular ganciclovir implants, physicians sometimes resort to using intra-ocular injections of ganciclovir [16] , which falls outside the recognized standard of care [2, 5] . Very little research has been done on CMV viremia in HIV-infected patients in RLS.
In this study, we aimed to assess the prevalence of CMV viremia in Thai ambulatory HIV-infected patients who started ART at CD4 counts <200 cells/mm 3 and to determine whether CMV viremia was associated with an increased risk of death or developing a new AIDS-defining illness (ADI) despite ART initiation. We assessed the evolution of CMV viremia after ART start and examined factors associated with its persistence.
METHODS

Study Design and Population
We conducted a retrospective study in the 006 prospective follow-up cohort study of patients enrolled in clinical trials at the HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) AIDS Research Center in Bangkok, Thailand, between 1996 and 2010. We measured CMV DNA in plasma specimens collected during these trials and stored at −70°C. We enrolled adult patients infected with human immunodeficiency virus type 1 (HIV-1) who had started or resumed (for patients who had discontinued ART) ART combination therapy at CD4 counts <200 cells/mm 3 and had frozen EDTA plasma specimens within 2 months of ART initiation or resumption. Patients at HIV-NAT have at least 6 monthly followup including CD4 counts and HIV-1 RNA measurements. Patients' data were retrieved from the secured HIV-NAT database.
Patients in the 006 cohort study had consented to blood specimens' storage during previous trials. All patients recruited in this study and still followed at HIV-NAT gave additional consent for CMV DNA testing on frozen specimens. The study was approved by the FHI360 and Chulalongkorn University ethical committees.
Laboratory Tests
Quantitative CMV DNA polymerase chain reaction (PCR) was performed at start of ART for all patients and at 6 months of ART for patients with available specimens. Previous findings support at least short-term stability of CMV DNA viral load in blood specimens stored at −20 and −70°C [19] . Stability of nucleic acids quantification over long-term cryopreservation has been shown for other viruses [20] . We allowed samples available within 2 months on either side of the study timepoints to be tested, to access a sufficient number of specimens, and because data had shown a median time to CMV viremia clearance of 13.5 weeks (range, 5-40 weeks) in HIV-infected patients started on ART with no CMV therapy [21] . CMV PCR tests were performed with the Abbott CMV PCR Kit on the Abbott m2000 system, according to the manufacturer's recommendations, at the HIV-NAT laboratory accredited by the College of American Pathologists. The assay used had a CMV DNA limit of detection (LOD) of 44 copies/mL.
Statistical Analysis and Endpoints
Statistical analysis was conducted with Stata version 11 (Statacorp, College Station, TX), and results were considered statistically significant at a 2-sided significance level of .05. Time to event methods were used to assess disease progression to each of 2 clinical endpoints, death and occurrence of a new ADI/ Centers for Disease Control and Prevention (CDC) stage C event (with addition of penicilliosis) after ART initiation. No distinction was made between CMV-related and CMVunrelated ADI, as very few diagnoses of the former were available. Analyses were based on intention to continue treatment, ignoring changes, or interruptions to treatment. Candidate predictor covariates screened were gender, age, an AIDS diagnosis vs CDC category A or B, baseline hemoglobin, plasma HIV-RNA, CD4 count, ART regimen, and plasma CMV DNA. Timing of CMV sample availability in relation to ART start was introduced as another covariate in the models as a sensitivity analysis. The Kaplan-Meier method was used for univariate screening of covariates and for assessing trend in continuous covariates. Thereafter we used Cox proportional hazards regression to assess the hazard ratios and 95% confidence intervals (CIs) for progression to each of the endpoints. Covariates significant in univariate analysis at P < .1 were adjusted for multivariate models. The proportional hazards assumption was assessed using Schoenfeld residuals. For subjects with CMV plasma samples available 6 months after initiating ART, multiple logistic regression was used to assess baseline characteristics associated with failure to clear CMV viremia.
RESULTS
Patients Characteristics
A total of 293 patients were included in this study (Table 1) ; 56.8% were males, and the median age was 33 years. The median baseline CD4 count and HIV-1 RNA levels were 82 cells/mm 3 (interquartile range [IQR], 28-145) and 4.9 log 10 copies/mL (IQR, 4.6-5.4), but only 23.7% had a CDC stage C disease at baseline. We note that candidate patients from the initial trials who could not be included in our study due to unavailability of stored specimens (n = 207) had slightly higher baseline CD4 counts (median, 113 cells/mm 3 ; IQR, 39-174) than our study patients (P = .004). Of 293 study patients, 273 (93.2%) were started on or resumed therapy with a potent ART combination: 134 of 273 patients (49.1%) received 2 nucleoside reverse transcriptase inhibitors (NRTIs) + 1 nonnucleoside , respectively (P < .001). Among 77 viremic patients, the median CMV DNA level was 548 copies/mL (IQR, 129-3849). The median time between CMV DNA testing and ART initiation was zero days (IQR, −14 days to 14 days), and CMV viremia was detected in 47 of 206 (22.8%) and 30 of 87 (34.5%) patients with blood samples available before and after ART start (P = .038). At 6 months into ART, CMV DNA testing was performed in 199 patients. CMV viremia was detected in only 9 of those (4.5%), and in 2 of 5 (40%), 4 of 33 (12.1%), and 1 of 66 (1.5%) of the patients with 6 months CD4 counts ≤50, between 51 and 100 and between 101 and 200 cells/mm 3 (P = .001). The median CMV DNA level was 114 copies/mL (IQR, 75-1099).
No patient received systemic anti-CMV therapy (1 patient received intraocular ganciclovir 2 months into ART for CMV retinitis). 
Factors Associated With Mortality and Morbidity
In sum, 6 of 8 deaths occurred in patients with CMV DNA >500 copies/mL, and 2 in patients with CMV DNA below the LOD. In univariate analysis, baseline characteristics associated with mortality included CDC staging C, hemoglobin <10 g/dL, lower CD4 counts, and CMV viremia ( Table 2 ). Plasma HIV-1 RNA was not associated with death in our study. No deaths occurred in patients on dual NRTI and in patients with blood collected after ART start. Neither variable was associated with the outcome or affected the final model and the death HR for CMV viremia. Because we had only 8 endpoints, power to derive an HR for death in consecutive strata of CMV DNA or define a viremia level most strongly associated with death was low. CMV DNA above the LOD (44 copies/mL) was associated with an increased death hazard ratio in univariate analysis, but this association was not statistically significant in multivariate analysis. Only higher-level viremia with CMV DNA >500 copies/mL (chosen because it was approximately the median, and 6 deaths occurred above that threshold) was significantly associated with mortality in both univariate ( Figure 1 ) and multivariate analysis, where it predicted a 7.3-fold increased risk (95% CI, 1.32-40.29) of mortality ( Table 2 ). The development of a new ADI was associated in univariate analysis with age, baseline CD4 count, and CMV viremia, although only at levels of CMV DNA >500 copies/mL (Table 3) . In multivariate analysis the association of high-CMV viremia with ADI did not hold significance, and only CD4 count remained significantly associated with this outcome.
Factors Associated With Lack of CMV Viremia Clearance on ART
Among the 199 patients with 6 months CMV DNA measurement, we found that only baseline hemoglobin <10 g/dL and CMV DNA >500 copies/mL were significantly associated with failure to clear CMV viremia by 6 months of ART in multivariate analysis (Table 4) .
DISCUSSION
In this study, we found a high prevalence of CMV viremia (26.3%) in Thai ambulatory HIV-infected patients starting ART with baseline CD4 count <200 cells/mm 3 . We showed that although most patients cleared CMV viremia by 6 months of ART without anti-CMV treatment, a baseline CMV DNA viremia >500 copies/mL was associated with a 7.3-fold increased risk of mortality. The prevalence of viremia decreased with increasing CD4 counts but was still substantial (10%) in patients with CD4 between 100 and 200 cells/mm 3 . CMV viremia was associated with mortality irrespectively of CD4 counts. CMV viremia was not associated with a statistically significant increased risk of developing a new ADI after ART initiation, which was only predicted by baseline CD4 counts.
To our knowledge, this is one of only 3 studies available on the prevalence and risks of CMV viremia in HIV-infected patients in developing countries. One study reported a prevalence of CMV viremia of 42.4% in a cohort of Cambodian adult HIV-infected patients. However, study patients had very advanced disease (45.9% were hospitalized patients), and not all received ART [22] . Another study in South Africa found increased mortality in association with CMV viremia in HIVinfected gold miners, but no patient received ART [23] . In our study, we aimed to select patients seemingly representative of patients starting ART in HIV treatment programs in RLS, in whom such data were not available.
Our data are consistent with reports from other settings. The prevalence of CMV viremia in our study resembles that seen in several studies (15%-34%) in severely immunosuppressed HIV-infected patients in high-income countries [11, 13-15, 24, 25] . The association between CMV viremia and increased mortality in HIV-infected patients, even in the context of ART, had also long been reported. Of 6 published studies that examined the association between CMV viremia and the risk of death in patients on combination ART in high-income countries [9, 11, [13] [14] [15] 25] , only 1 found no such association [11] . Most importantly, in all 3 studies (including our) that used CMV DNA quantitative assays, an association was found between the risk of mortality and levels of CMV viremia [22, 25] . In our study, only CMV DNA >500 copies/mL (2.7 log 10 ) was associated with an increased risk of death. In the Cambodian study, mortality was only increased in patients with CMV DNA ≥3.1 log 10 copies/mL and tended to further increase with Figure 1 . Kaplan-Meier figure of probability of death by cytomegalovirus plasma concentration at antiretroviral therapy start. Abbreviations: ARV, antiretroviral; CMV, cytomegalovirus. higher viremia levels [22] . In a Swiss cohort study, El Amari et al [25] found a death hazard ratio of 1.9 and 3.9 in patients with CMV DNA above 80 and 1000 copies/mL, respectively. We add that the relationship between increasing levels of CMV viremia and mortality had been observed before the use of potent ART [26, 27] . The pathogenicity driving the association between CMV viremia and mortality in HIV-infected patients is insufficiently understood. Although CMV has not been reported as a significant cause of death in previous studies, we agree that CMV viremia could be associated with direct CMV pathogenic effects underestimated in their contribution to death [14, 15] . Several studies have reported important pre-mortem underdiagnosis of CMV disease in HIV-infected patients, and recognition of the disease only at autopsy [28] [29] [30] [31] [32] . However, CMV viremia could also be a cause, or a consequence, of poor immune function [14, 15, 25] , and it is possible that other diseases leading or contributing to death could cause immunosuppression and CMV reactivation.
We acknowledge several limitations in our study. First, we observed only a few mortality events during follow-up, and as such the association found between CMV viremia and increased mortality must be interpreted with caution. As patients included in our study had passed selection criteria for participation in clinical trials, they may not have fully represented patients receiving care in routine services. In turn, our study patients were included upon availability of frozen plasma specimens and had slightly lower CD4 counts than potential candidates for whom specimens were unavailable. These 2 limitations may have inversely played to under-and overestimate the association between CMV viremia with clinical outcomes. We could not evaluate the association between CMV viremia and CMV end-organ disease (EOD), as only 2 events were diagnosed during the study period. Fundoscopy for patients with CD4 <100 cells/mm 3 was not systematic during the study period, and investigations for possible extraocular CMV-EOD were not conducted at the study site, as is the case in most RLS. Therefore, CMV disease is likely to have been underdiagnosed in our study population. Episodes of hospitalizations could have perhaps represented a surrogate indicator of CMV morbidity (as a result of nonspecific symptoms and signs of CMV disease), but this endpoint was unavailable in our database and could not be studied. Data were missing for some other variables and some patients. Body weight was unavailable for some 25% of patients and therefore not included in our analysis. Six months CMV DNA was not measured for a significant proportion of patients, representing a weakness of our analysis of CMV DNA change between the 2 study timepoints. Our study may have nevertheless significant implications for HIV care in the developing world, offering complementary information on an already compelling issue. Despite the lack of attention that CMV disease in RLS has received, studies do show that the burden of CMV retinitis alone is significant in these settings [16] [17] [18] . Through systematic screening, a study in Myanmar found a prevalence of CMV retinitis of 24% among new HIV-infected patients with CD4 <100 cells/mm 3 [33] .
Another study reported a high incidence of CMV retinitis in AIDS patients in Togo [34] . The clinical impact of the disease is likely underestimated or underreported. A study conducted in Thailand in 2005 found CMV retinitis to be the second most common cause of blindness and low vision (following cataract) in a general tertiary ophthalmology center [35] . CMV extraocular manifestations likely cause additional unrecognized morbidity and mortality [16] . We now found that CMV viremia was associated with early mortality in severely immunosuppressed patients starting ART in Thailand, which has indeed potential significant implications in light of the substantial early mortality that is still observed in ART programs in RLS in patients with severe immunosuppression [36, 37] . We suggest that a large-scale prospective study be conducted to better document the extent of the problem of CMV viremia in severely immunosuppressed HIV-infected patients in RLS. This remains fully relevant. Despite evolving recommendations to initiate ART earlier in the course of HIV infection, patients in developing countries continue to present with very advanced HIV disease or are started on ART at low levels of CD4 cell counts. A recent global analysis in 309 435 patients from 48 countries showed that in 2010, the median CD4 cell count at ART start was still well below 200 cells/mm 3 in low-and middle-income countries [38] . In addition, as Deayton et al [14] already suggested in 2004, we believe that a randomized clinical trial (RCT) of preemptive valganciclovir therapy should be conducted in CMV viremic, severely immunosuppressed HIV patients starting ART. To date, only 1 RCT has attempted to study the effects of preemptive anti-CMV therapy in HIVinfected patients in the context of combination ART. Only 47 patients were included in the study, which was prematurely interrupted for futility by an independent data and safety monitoring board [39] . We believe that a well-powered trial is required to convincingly answer if preemptive therapy could reduce early mortality in CMV-viremic HIV patients starting ART.
Notes
